4.41

0.90% -0.04

Savara Inc (SVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Savara Inc stock is currently priced at $4.41, with a 24-hour trading volume of 400.12K. It has seen a -0.90% decreased in the last 24 hours and a -10.18% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.32 pivot point. If it approaches the $4.59 resistance level, significant changes may occur.

Previous Close:

$4.45

Open:

$4.48

24h Volume:

400.12K

Market Cap:

$609.23M

Revenue:

Net Income/Loss:

$-54.70M

P/E Ratio:

-15.75

EPS:

-0.28

Net Cash Flow:

$-51.36M

1W Performance:

-8.32%

1M Performance:

-10.18%

6M Performance:

+25.64%

1Y Performance:

+143.65%

1D Range:

$4.365

$4.51

52W Range:

$1.7851

$5.70

Savara Inc Stock (SVRA) Company Profile

Name

Savara Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

512-961-1891

Address

Building 3, Suite 200 6836 Bee Cave Road, Austin, TX

Employee

Twitter

@SavaraPharma

Next Earnings Date

2024-05-13

Latest SEC Filings

SVRA's Discussions on Twitter

Savara Inc Stock (SVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-23	Initiated	Guggenheim	Buy
May-16-23	Upgrade	Jefferies	Hold → Buy
Mar-31-23	Downgrade	Jefferies	Buy → Hold
Mar-16-21	Initiated	Piper Sandler	Overweight
Mar-15-21	Initiated	Oppenheimer	Outperform
Jun-13-19	Reiterated	H.C. Wainwright	Buy
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-13-18	Resumed	ROTH Capital	Neutral
Jan-03-18	Initiated	Ladenburg Thalmann	Buy
Sep-27-17	Resumed	ROTH Capital	Buy
Sep-22-17	Initiated	Jefferies	Buy
Sep-11-17	Initiated	JMP Securities	Mkt Outperform

View All

Savara Inc Stock (SVRA) Latest News

Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday

Benzinga

Savara Inc Stock (SVRA) Financials Data

Savara Inc (SVRA) Net Income 2024

SVRA net income (TTM) was -$54.70 million for the quarter ending December 31, 2023, a -43.38% decrease year-over-year.

Savara Inc (SVRA) Cash Flow 2024

SVRA recorded a free cash flow (TTM) of -$51.36 million for the quarter ending December 31, 2023, a -48.59% decrease year-over-year.

Savara Inc (SVRA) Earnings per Share 2024

SVRA earnings per share (TTM) was -$0.33 for the quarter ending December 31, 2023, a -32.00% decline year-over-year.

Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial and lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant staphylococcus aureus lung infection in individuals living with cystic fibrosis. The company is headquartered in Austin, Texas.